Vaccine Adjuvant Compendium—Resource To View and Submit Adjuvant Metadata

Funding News Edition: May 19, 2021
See more articles in this edition

Vaccine developers, you can identify suitable adjuvants and share your own adjuvant characteristics (metadata) through NIAID’s Vaccine Adjuvant Compendium (VAC).

As described in the NIAID Strategic Plan for Research On Vaccine Adjuvants, NIAID has an ongoing and significant interest in supporting new vaccine adjuvants. Earlier this year, NIAID’s Division of Allergy, Immunology, and Transplantation and Office of Cyber Infrastructure and Computational Biology launched the VAC to foster collaborations between NIAID-supported adjuvant researchers and the broader scientific community.

The VAC displays adjuvant characteristics for various vaccine indications, including immune-mediated and infectious diseases.  

How To Use the VAC

Go to the VAC Home Page, which features three major sections:

  • Search: Includes options for keyword, receptor, immune profile, pathogen, product grade, and clinical trials.
  • Browse: Lists recently added or updated adjuvants.
  • Metrics: Provides VAC data as interactive graphs by disease, pathogens, and adjuvant receptors.

In Browse view, you can filter using keyword, receptor, immune profile, pathogen, product grade, and clinical trials. The Download button on the upper right exports your search results in MS Excel format.

To get full details on each adjuvant shown, click the linked name. Check out Alhydroxiquim-II as a typical example:

  • Scroll through the entry for the point of contact, description, in vivo use (preclinical), links to associated publications, product grade and formulation, clinical trial information, and more.
  • Use the Product Sheet button on the upper right to generate a custom PDF summary.

Speaking of Alhydroxiquim-II, 13 countries have approved its use in COVID vaccines.

Submit Your Adjuvant Information to the VAC

Currently, the VAC’s information is primarily from adjuvant developers with NIAID-funded studies. That said, all researchers are welcome to include their adjuvant in the VAC.

If you’d like to contribute information about your adjuvant or ask questions, contact

Use the About Us button shown on the upper right of the VAC website for a summary and links to NIAID’s solicited adjuvant research programs.

In a future article, we will cover adjuvant-related funding opportunities such as the following:

Contact Us

Email us at for help navigating NIAID’s grant and contract policies and procedures.

Content last reviewed on